Quantcast
Last updated on April 16, 2014 at 7:44 EDT

Latest Affymax Inc. Stories

2008-08-28 18:00:51

Affymax, Inc. (Nasdaq:AFFY) today announced that Affymax management will host a conference call and webcast at 5:00 p.m. Eastern Time today. The call will discuss the joint Affymax and Takeda decision to focus all development efforts for Hematide(TM) on the treatment of anemia associated with chronic kidney disease and to suspend co-development of Hematide(TM) to treat chemotherapy-induced anemia. Hematide(TM) is a novel, synthetic pegylated peptide-based erythropoiesis stimulating agent...

2008-08-28 09:01:23

Affymax, Inc. (Nasdaq:AFFY) today announced the Company's participation at the following investor conferences during the month of September. Thomas Weisel Partners Healthcare Conference 2008 Four Seasons Hotel, Boston September 3 8:35 a.m. Eastern Time BioCentury Newsmakers in the Biotech Industry Conference Millennium Broadway Hotel, New York City September 4 3:30 p.m. Eastern Time Morgan Stanley Global Healthcare Unplugged Conference Grand Hyatt New York September 9 1:35 p.m. Eastern...

2008-08-07 18:01:54

Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data Monitoring Committee (DMC), which provides oversight for the Phase 3 program for Hematide(TM), has completed its first review of the data and informed the company that the cumulative safety data generated thus far from the EMERALD and PEARL Phase 3 trials support continuation of the studies. In the Phase 3 program, Hematide is being evaluated to treat anemia in chronic renal failure patients on dialysis and not on dialysis....

2008-07-09 09:01:01

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, Hematide(TM), which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 1 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 475 non-dialysis patients from over 70 sites in the United States. "We are delighted that the rate of enrollment...

2008-06-30 09:03:37

Affymax, Inc. (Nasdaq:AFFY) today announced that enrollment has begun in a Phase 2 clinical trial of Hematide(TM) to correct anemia in patients with chronic renal failure (CRF) who are undergoing dialysis and are not actively being treated with an erythropoiesis stimulating agent (ESA). The trial is intended to generate data for Hematide as an anemia correction therapy in this segment of the CRF patient population, some of whom may be ESA-naive. This is the first Hematide correction study in...